Ocular TherapeutixTM Reports Second Quarter 2026 Financial Results and Business Highlights
· ocular therapeutix, inc.
Source Summary
Ocular’s AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026
Advertisement